Inquiry Basket
CAS No.:
Cat No.: BADC-01345
4.5 
MC-Val-Ala-SG3199 is a potent cytotoxic compound. It is a potent, selective, irreversible inhibitor with a high reputation in the biomedical field. Its most important significance is in the fight against cancer, especially those that are refractory to traditional treatments. This compound triggers cell death by specifically targeting an enzyme that plays a key role in the ominous expansion and proliferation of tumors.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
MC-Val-Ala-SG3199 is a synthetic peptide conjugate used in targeted cancer therapies. Here are some key applications of MC-Val-Ala-SG3199:
Targeted Cancer Therapy: MC-Val-Ala-SG3199 is designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. This approach increases the efficacy of chemotherapy by concentrating the drug’s action specifically where it’s needed. By linking SG3199, a potent warhead, to a peptide recognizer like MC-Val-Ala, this compound enhances selectivity and reduces systemic toxicity.
Immuno-oncology: In immuno-oncology, MC-Val-Ala-SG3199 can be used to modulate the immune response against tumors. By delivering the conjugate to immune cells within the tumor microenvironment, it enhances the immune cells’ ability to identify and destroy malignant cells. This can lead to improved outcomes in cancer treatment through cooperation with other immune-based therapies.
Combination Therapy Research: MC-Val-Ala-SG3199 is frequently studied in combination with other therapeutic agents to identify synergistic effects. Researchers explore how the conjugate works alongside different classes of drugs, such as checkpoint inhibitors, to amplify anti-tumor activity. Combining this peptide conjugate with other treatments could potentially lead to more effective and personalized therapeutic strategies in oncology.
Bioconjugation Technology: The use of MC-Val-Ala-SG3199 exemplifies the advancements in bioconjugation technology, allowing for precise delivery systems in drug development. Researchers study methodologies to optimize the linking of active agents to targeting moieties like peptides, thereby improving the stability and bioavailability of therapeutic compounds. This application is central to the creation of next-generation biologic drugs with enhanced capabilities.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01353 | SG3199 | 1595275-71-0 | |
| BADC-00741 | MA-PEG8-VA-PAB-SG3199 | ||
| BADC-00766 | DBCO-PEG8-VA-PAB-SG3199 |
What is MC-Val-Ala-SG3199?
MC-Val-Ala-SG3199 is a DNA-alkylating cytotoxin used in ADCs. It induces DNA crosslinking and apoptosis in target cells. Its chemical design allows conjugation to antibodies, enabling targeted delivery and enhanced therapeutic potency in oncology applications.
14/5/2022
Dear BOC Sciences, could you explain how MC-Val-Ala-SG3199 improves ADC performance?
By serving as a highly potent payload, MC-Val-Ala-SG3199 enhances ADC efficacy by selectively killing tumor cells. Its delivery via antibodies ensures minimal off-target effects, maximizing therapeutic benefit while maintaining safety in preclinical and clinical contexts.
5/10/2016
Dear BOC Sciences, could you advise which linkers are suitable for MC-Val-Ala-SG3199?
MC-Val-Ala-SG3199 is compatible with peptide-based cleavable linkers that respond to intracellular proteases. These linkers ensure controlled payload release within the target cell, contributing to ADC stability in circulation and effective cytotoxic activity.
21/6/2018
Is MC-Val-Ala-SG3199 applicable in preclinical ADC research?
Yes, MC-Val-Ala-SG3199 is widely used in preclinical ADC studies to assess efficacy, safety, and payload release kinetics. It provides critical insights for optimizing ADC design and predicting clinical performance.
14/5/2020
Dear team, what safety measures are essential for MC-Val-Ala-SG3199?
Due to its high cytotoxicity, handling MC-Val-Ala-SG3199 requires strict safety protocols, including PPE, fume hoods, and controlled waste disposal. These measures minimize risk to personnel and ensure safe laboratory operations.
14/5/2019
— Dr. James Parker, Lead Scientist (USA)
MC-Val-Ala-SG3199 from BOC Sciences arrived with outstanding purity, supporting our ADC conjugation studies.
21/6/2018
— Dr. Jonathan Reed, Oncology Scientist (USA)
MC-Val-Ala-SG3199 was instrumental in our preclinical research. Its high activity and purity were critical to our success.
14/5/2019
— Ms. Emma Johansson, Researcher (Sweden)
Our experience with MC-Val-Ala-SG3199 was excellent. The compound arrived on time and performed as expected in assays.
14/5/2020
— Mr. Lucas Meyer, Biotech Specialist (Germany)
MC-Val-Ala-SG3199 provided consistent conjugation results, giving us confidence to progress into later project stages.
14/5/2022
— Dr. Elena García, QA Scientist (Spain)
The analytical data supplied with MC-Val-Ala-SG3199 was comprehensive, helping us meet strict internal quality checks.
— Mr. Mark Stevens, Senior Scientist (UK)
BOC Sciences’ reliable delivery of MC-Val-Ala-SG3199 kept our ADC development timelines on track.
5/10/2016
MC-Val-Ala-SG3199
Required fields are marked with *
MC-Val-Ala-SG3199
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
